Paul has worked in clinical development for over 25 years in large pharma, CRO and biotech settings. His work spans all phases of drug development and he is a recognised thought leader in drug development, patient engagement and clinical development. He has played significant roles in the development and approval of several drugs in addition to also working extensively on process design and quality management systems.
Paul currently is Chief Development Officer at two early stage biotech companies, ResoTher Pharma and Roxiant developing treatments in acute cardiovascular syndromes and gene therapy for rare neurodegenerative disease respectively. He is a member of the Board of Directors for Proxi Biotech, a vaccine company and a scientific advisor for NoviPel, a medtech company. Paul is also a Domain Expert for the University of Copenhagen Innovation Hub.
Paul holds an MSc in Clinical Pharmacology from the University of Aberdeen and an MBA from Copenhagen Business School.
Having previously lived and worked in the UK and Japan Paul now lives outside Copenhagen enjoying the Scandinavian lifestyle and outdoors with his family.